Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, im going to discuss my 3 worst stock market picks based on the mistakes I've made and what I learned from them.

2 extracted signals · 2 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor10 Aug 2025, 17:23 UTC
Video preview for Friends! In this video, im going to discuss my 3 worst stock market picks based on the mistakes I've made and what I learned from them.
Signals
2
Eligible signals in this source
Open
0
Still being tracked
Resolved
2
Evaluable outcomes
Successful
1
Canonical correct result
Failed
1
Canonical failed result
Resolved success
50%
Open and excluded signals omitted
Source overview

AI-generated source summary

The analysis focuses on three stocks (UNH, WALMEX and MUSA), providing insight on investment mistakes. The first stock discussed is UnitedHealth Group (UNH). The analyst bought UnitedHealth at $420 per share. The current share price is $244.67, representing a 41% decline. It is suggested investors need a catalyst for growth and may need a President to endorse stocks before people buy. For Wal-Mart de Mexico (WALMEX), a 6% loss after the stock price remained stagnant over five years. For Murphy USA(MUSA), the investors didn't focused on quality. AutoZone (AZO) was a better option but was more expensive than MUSA, which currently trades around $377. Inferred targets are also provided.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  4. Market predictions extracted

    2 eligible signals linked to this case.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.